2-piperazin-1-yl-6-trifluoromethoxy-quinoline hydrochloride | 1179806-77-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-piperazin-1-yl-6-trifluoromethoxy-quinoline hydrochloride
• CAS: 1179806-77-9
• 化学式: C₁₄H₁₄F₃N₃O*ClH
• 分子量: 333.741
• InChiKey: DUHMKSZXAFBWEK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.96
• 重原子数：
  22.0
• 可旋转键数：
  2.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  37.39
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  (2R)-quinaldine dioxine brosylate 、 2-piperazin-1-yl-6-trifluoromethoxy-quinoline hydrochloride 以 二甲基亚砜 为溶剂， 反应 12.0h， 以77%的产率得到(2S)-8-methyl-2-({4-[6-(trifluoromethoxy)quinolin-2-yl]piperazin-1-yl}methyl)-2,3-dihydro-[1,4]dioxino[2,3-f]quinoline
  参考文献：
  名称：

  Synthesis, Potency, and in Vivo Evaluation of 2-Piperazin-1-ylquinoline Analogues as Dual Serotonin Reuptake Inhibitors and Serotonin 5-HT_1A Receptor Antagonists

  摘要：

  On the basis of the previously reported clinical candidate, SSA-426 (1), a series of related 2-piperazin-1-ylquinoline derivatives 3-16 were synthesized and evaluated as dual-acting serotonin (5-HT) reuptake inhibitors and 5-HT1A receptor antagonists. In particular, compound 7 exhibits potent functional activities at both the 5-HT transporter and 5-HT1A receptor, good selectivity over the alpha(1)-adrenergic and dopaminergic receptors, acceptable pharmacokinetic properties, and a favorable in vivo profile.

  DOI：

  10.1021/jm900374r
• 作为产物：
  描述：

  哌嗪 、 2-氯-6-(三氟甲氧基)喹啉 以 N,N-二甲基甲酰胺 为溶剂， 以92.6%的产率得到2-piperazin-1-yl-6-trifluoromethoxy-quinoline hydrochloride
  参考文献：
  名称：

  Synthesis, Potency, and in Vivo Evaluation of 2-Piperazin-1-ylquinoline Analogues as Dual Serotonin Reuptake Inhibitors and Serotonin 5-HT_1A Receptor Antagonists

  摘要：

  On the basis of the previously reported clinical candidate, SSA-426 (1), a series of related 2-piperazin-1-ylquinoline derivatives 3-16 were synthesized and evaluated as dual-acting serotonin (5-HT) reuptake inhibitors and 5-HT1A receptor antagonists. In particular, compound 7 exhibits potent functional activities at both the 5-HT transporter and 5-HT1A receptor, good selectivity over the alpha(1)-adrenergic and dopaminergic receptors, acceptable pharmacokinetic properties, and a favorable in vivo profile.

  DOI：

  10.1021/jm900374r